TOPIC
Rare Diseases
3 stories covering rare diseases — fund closes, LP allocations, regulatory filings, deal flow, and fundraising signals from PipelineRoad's editorial team.
Neurocrine Acquires Soleno for $2.9 Billion to Add PWS Drug
Neurocrine Biosciences expands its rare disease portfolio through a $2.9 billion acquisition of Soleno Therapeutics, gaining Vykat XR for Prader-Willi syndrome.
Neurocrine Acquires Soleno for $2.9 Billion to Gain Vykat XR
Neurocrine Biosciences expands its rare disease portfolio by acquiring Soleno Therapeutics for $2.9 billion, adding Vykat XR for Prader-Willi syndrome.
Zevra Therapeutics Sells SDX Portfolio to Commave for $50 Million
Zevra Therapeutics announced the sale of its SDX portfolio, including AZSTARYS and KP1077, to Commave Therapeutics for $50 million on March 16, 2026, settling a prior lawsuit.
Daily capital raising signals
Get fund close, LP allocation, and deal flow news before it hits the mainstream.
